Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT04699188 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04699188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04699188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 24, 2021
Completion date
January 25, 2027
Enrollment
344 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of lung, cancer of the lung, carcinoma, colorectal, carcinoma, non-small-cell lung, kras g12c mutant solid tumors, lung cancer, neoplasms, lung, neoplasms, pulmonary, pulmonary cancer, pulmonary neoplasms